FINANCIAL POST ARTICLETHIS SAYS IT ALL:
Mr. MacNicol said. "It's a classic grower, is very profitable and we expect it will be paying a dividend by the end of the year."
Post says MacNicol keen on Patient Home Monitoring
2015-02-18 06:53 ET - In the News
The Financial Post reports in its Wednesday edition David MacNicol at MacNicol & Associates Asset Management says buy Patient Home Monitoring ($1.02). The Post's Jonathan Ratner, writing in Buy & Sell, says Mr. MacNicol first bought the stock at its initial financing and has been in on all of its subsequent financings. Patient Home Monitoring's roll-up strategy involves buying small health-care businesses in areas such as pulmonary disease, sleep disorders, reduced mobility and other chronic health conditions. "They've done some quite successful cross-selling and the demographic picture is very strong," Mr. MacNicol said. "It's a classic grower, is very profitable and we expect it will be paying a dividend by the end of the year." Over all, the portfolio manager is focusing on U.S. companies that will not be hindered by the strong greenback, but is also seeing some opportunities abroad, especially in India and South Korea. "Many multinationals are having to deal with declining global currencies," he said. "That's starting to show up in their earnings." As a result, Mr. MacNicol is positioning his client portfolios in Canadian and U.S. companies that have the bulk of their sales south of the border.